BioStock - Connecting Innovation & Capital

Novo Nordisk is halting the phase III trials Hermes and Athena of ziltivekimab, both in heart failure. The decision came after the trials’ data monitoring committee concluded there was little chance of a different outcome from the failed Zeus study. One trial now remains in the programme, and with it Novo’s hopes of building a business beyond obesity and diabetes.

Novo scraps two more phase III trials of ziltivekimab Ziltivekimab is a fully human monoclonal antibody targeting interleukin-6, one of the body's key inflammatory signals. The idea behind it rests on a hypothesis that has gained traction in cardiology over the past couple of decades: that inflammation itself drives atherosclerosis, and with it the ris...

🔥 redhot diagnostics AB on their next step

RedHot Diagnostics develops and sells diagnostic products with the aim of improving diagnostics and patient care. BioStock invited board member Henrik Rundgren to BioStock’s studio to talk more about the technology behind the kit, which customers the company is targeting, and where development currently stands.

Watch the interview ➡️

https://biostock.se/en/2026/09/redhot-diagnostics-on-their-next-step/

📬 Dagens Nyhetssvep från BioStock!

🔹 Novo Nordisk presenterar fas III-data från STEP Young där 40,4 procent av barnen med fetma nådde ett BMI under fetmagränsen med semaglutid i kombination med livsstilsförändringar.
🔹 SynAct Pharma meddelar att ytterligare analys av fas IIb-studien ADVANCE stärker resultaten från fas IIb-studien EXPAND och stödjer utveckling i fas III, med diskussioner med FDA om studiedesign planerade till Q4 2026.
🔹 Glycorex Transplantation AB (publ) Transplantation ingår distributionsavtal i Brasilien för Glycosorb ABO.

Håll dig uppdaterad – läs hela Svepet hos BioStock.

biostock.se

📊 BioStock Analytics has published a new Consensus Analysis — this time on Novonesis.

Following the H1 2026 report on 19 August, in which Novonesis raised its full-year organic growth outlook to 7–8 per cent and approved a EUR 1 billion buyback, seven of the twelve houses in the panel have revised their targets — six of them upward.

The panel median now stands at 500 DKK, implying 14.7 per cent upside on the closing price of 435.90 DKK. Ten of the twelve houses in the window carry a Buy, two a Hold, and none a Sell. The sole downward revision came from BNP Paribas, the only house with a target below the current share price.

Read the full analysis at

Consensus Analysis | Novonesis | 2026-09-08 | Publicerad idag 08:37 Consensus Analysis | Novonesis | 2026-09-08 Text: Redaktion | [email protected] Consensus Analysis · 8 September 2026 Novonesis A/S · inside the range, below the median Novonesis raised its full-year organic growth outlook to 7 to 8 per cent alongside its H1 report on 19 A...

Prolight Diagnostics has signed a supply agreement with BRAINBox Solutions, Inc. covering Psyros instruments and cartridges. First-year deliveries following FDA clearance and market launch are valued at USD 3.9 million, around SEK 37 million, with volumes expected to rise from year two.

In March, the two companies initiated an analytical evaluation of three TBI biomarkers on the Psyros platform. This summer, a SEK 29 million development agreement and moves the collaboration from development into commercial supply. Now, they have a supply agreement in place.

BioStock spoke to Prolight CEO Ulf Bladin about the collaboration, what the volume ramp depends on, and what a clearance of the BRAINBox system would mean for the Psyros platform beyond traumatic brain injury.

Read the interview:

Prolight comments on USD 3.9m BRAINBox deal Prolight develops the point-of-care system Psyros, a point of care platform that counts individual molecules digitally from a single drop of blood, capable of measuring biomarkers at single nanogram per liter detection levels in ten minutes or less. The company's original lead application is high-se...

Alligator Bioscience AB lägger ned den egna utvecklingen av huvudkandidaten mitazalimab. I stället koncentreras resurserna kring det utlicensierade HLX22-projektet. Omställningen finansieras genom en företrädesemission om initialt cirka 125,6 Mkr, med teckningsperiod 4–18 september. Förändringen innebär ett fundamentalt skifte i affärsmodellen – från egen klinisk utveckling till förvaltning av ett royaltyintresse.

Alligator genomför företrädesemission efter strategisk omställning Lundabaserade Alligator Bioscience har historiskt varit inriktat på tumörriktad immunonkologi. Efter den strategiska omorienteringen är bolagets huvudsakliga värdedrivare i stället det ekonomiska intresset i HLX22, en HER2-riktad monoklonal antikropp som utvecklas av det kinesiska bolaget Shang...

Medtech4Health har tagit fram en nationell bild av det medicintekniska innovationssystemet i Sverige. kartläggningen visar var lösningarna fastnar – och det är sällan i tekniken. Det svåraste steget är implementeringen i vården, långt efter CE-märkningen. För tidiga bolag är det också där tidsplaner och kapitalbehov oftast underskattas.

– Följden blir långa kommersialiseringsprocesser, innovationer som fastnar i ”dödens dal” och bolag som söker sig till andra marknader, säger Lena Strömberg, programdirektör för Medtech4Health.

Läs hela artikeln på

Nu kartläggs Sveriges medicintekniska ekosystem Svensk medicinteknik omsatte 315 miljarder kronor under 2025, en uppgång med 1 procent mot 2024 och 23 procent sedan 2021. Branschen sysselsätter totalt 38 700 personer och omfattar drygt 2 100 bolag, en ökning med 5 procent på bara ett års tid. Branschens totala resultat landade på 38 miljard...

📬 Dagens Nyhetssvep från BioStock!

🔹 AstraZeneca har fått godkännande i USA för Etcamah i kombination med en CDK4/6-hämmare som förstahandsbehandling vid avancerad HR-positiv bröstcancer.
🔹 Neola Medical har tilldelats FDA Breakthrough Device Designation.
🔹 Prolight Diagnostics har tecknat ett leveransavtal med BRAINBox värt 3,9 MUSD (37 Mkr) under det första året.

Håll dig uppdaterad – läs hela Svepet hos BioStock.

Nyhetssvepet måndag 7 september AstraZeneca har fått godkännande i USA för Etcamah i kombination med en CDK4/6-hämmare som förstahandsbehandling vid avancerad HR-positiv bröstcancer. Läs mer. Bioretec har erhållit FDA 510(k)-godkännande för sin bioabsorberbara kompressionsskruv ActivaScrew Cannulated COM. Läs mer. Colop...

This week's 🧬Nordic Pulse🧬 is once again headlined by AstraZeneca, which delivered three distinct disclosures: EU approval of Enhertu plus pertuzumab in first-line HER2-positive metastatic breast cancer, a positive phase III readout for Tagrisso plus Orpathys in MET-overexpressing EGFR-mutated lung cancer, and completion of a global licence for oral EGFR inhibitor Zegfrovy.

Meanwhile;
🧠 BioArctic's Leqembi secured two international milestones – a reimbursement recommendation in Canada and a Chinese approval – broadening the global commercial pathway for the Alzheimer's therapy.
⏳ Cinclus Pharma completed the treatment period in its phase III HEEALING1 study, with topline results expected in Q4 2026 – placing the company at a key inflection point for its lead gastric-acid programme.
💰 Thor Medical ASA completed a private placement and retail offering of NOK 300 million, with a subsequent public offering under consideration.
📅 Sedana Medical disclosed its FDA PDUFA target action date as 16 April 2027, while Neola Medical received FDA Breakthrough Device Designation – both advancing US regulatory pathways for Nordic medtech companies.

Read the full report at

AstraZeneca strikes again, BioArctic's Leqembi goes global and Cinclus holds its breath – the Nordic Pulse | 2026:36 | Publicerad idag 07:46 AstraZeneca strikes again, BioArctic’s Leqembi goes global and Cinclus holds its breath – the Nordic Pulse | 2026:36 Text: Redaktion | [email protected] B BIOSTOCK ANALYTICS Nordic Life Science Weekly Key Insights 1. Market Snapshot 2. Major Events 3. Financial Impact 4....

EDITORIAL: After several lean years, the sector has come back to life. Alongside the highest number of listings since the peak year of 2021, the back door onto the market has been thrown wide open. The trend is clearest internationally, but there are early signs of movement in the Nordics too.

https://biostock.se/en/2026/09/biotech-is-heading-back-to-the-stock-market/